Literature DB >> 8769427

Sequential regulation of alpha 4 beta 1 and alpha 5 beta 1 integrin avidity by CC chemokines in monocytes: implications for transendothelial chemotaxis.

C Weber1, R Alon, B Moser, T A Springer.   

Abstract

Leukocyte emigration possibly requires dynamic regulation of integrin adhesiveness for endothelial and extracellular matrix ligands. Adhesion assays on purified vascular cell adhension molecule (VCAM)-1, fibronectin, and fibronectin fragments revealed distinct kinetic patterns for the regulation of very late antigen (VLA)-4 (alpha 4 beta 1) and VLA-5 (alpha 5 beta 1) avidity by the CC chemokines monocyte inflammatory protein (MIP)-1 alpha, RANTES (regulated on activation, normal T expressed and secreted), or monocyte chemoattractant protein (MCP)-1 in monocytes. CC chemokines induced early activation and subsequent deactivation of VLA-4, whereas upregulation of VLA-5 avidity occurred later and persisted. Controlled detachment assays in shear flow suggested that adhesive strength of VLA-4 for VCAM-1 or the 40-kD fragment of fibronectin (FN40) is more rapidly increased and subsequently reduced by MCP-1 than by MIP-1 alpha, and confirmed late and sustained activation of the adhesive strength of VLA-5 for the 120-kD fragment of fibronectin (FN120). Mn2+ or the stimulating beta 1 mAb TS2/16 strongly and stably enhanced monocyte binding to VCAM-1 or fibronectin, and locked beta 1 integrins in a high avidity state, which was not further modulated by CC chemokines. Mn2+ and mAb TS2/16 inhibited CC chemokine-induced transendothelial migration, particularly chemotaxis across stimulated endothelium that involved VLA-4 and VCAM-1. VLA-4 on Jurkat cells is of constitutively high avidity and interfered with migration across barriers expressing VCAM-1. Low but not high site densities of VCAM-1 or FN40 promoted, while FN120 impaired, beta 1 integrin-dependent monocyte chemotaxis to MCP-1 across filters coated with these substrates. Thus, we show that CC chemokines can differentially and selectively regulate avidity of integrins sharing common beta subunits. Transient activation and deactivation of VLA-4 may serve to facilitate transendothelial diapedesis, whereas late and prolonged activation of VLA-5 may mediate subsequent interactions with the basement membrane and extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8769427      PMCID: PMC2120967          DOI: 10.1083/jcb.134.4.1063

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  64 in total

1.  VLA-3: a novel polypeptide association within the VLA molecular complex: cell distribution and biochemical characterization.

Authors:  F Sánchez-Madrid; M O De Landázuri; G Morago; M Cebrián; A Acevedo; C Bernabeu
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

2.  The isolation and characterization of the human helper inducer T cell subset.

Authors:  C Morimoto; N L Letvin; A W Boyd; M Hagan; H M Brown; M M Kornacki; S F Schlossman
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

3.  Vascular cell adhesion molecule (VCAM)-Ig fusion protein defines distinct affinity states of the very late antigen-4 (VLA-4) receptor.

Authors:  A Jakubowski; M D Rosa; S Bixler; R Lobb; L C Burkly
Journal:  Cell Adhes Commun       Date:  1995-05

4.  Isolation of human blood monocytes with Nycodenz, a new non-ionic iodinated gradient medium.

Authors:  A Bøyum
Journal:  Scand J Immunol       Date:  1983-05       Impact factor: 3.487

5.  Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines.

Authors:  M E Hemler; F Sanchez-Madrid; T J Flotte; A M Krensky; S J Burakoff; A K Bhan; T A Springer; J L Strominger
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

6.  Molecular mechanisms of lymphocyte extravasation. I. Studies of two selective inhibitors of lymphocyte recirculation.

Authors:  G J Spangrude; B A Braaten; R A Daynes
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

7.  Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3.

Authors:  F Sanchez-Madrid; A M Krensky; C F Ware; E Robbins; J L Strominger; S J Burakoff; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  Expression of myeloid differentiation antigens on normal and malignant myeloid cells.

Authors:  J D Griffin; J Ritz; L M Nadler; S F Schlossman
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  Synthesis of fibronectin by cultured human endothelial cells.

Authors:  E A Jaffe; D F Mosher
Journal:  J Exp Med       Date:  1978-06-01       Impact factor: 14.307

View more
  52 in total

1.  Role of stromal-cell derived factor-1 in the development of autoimmune diseases in non-obese diabetic mice.

Authors:  Khairul Matin; M Abdus Salam; Joynab Akhter; Nobuhiro Hanada; Hidenobu Senpuku
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

2.  Fibronectin-mononuclear cell interactions regulate type 1 helper T cell cytokine network in tolerant transplant recipients.

Authors:  A J Coito; K Onodera; H Kato; R W Busuttil; J W Kupiec-Weglinski
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Chemokines induce the cellular migration of MCF-7 human breast carcinoma cells: subpopulations of tumour cells display positive and negative chemotaxis and differential in vivo growth potentials.

Authors:  S J Prest; R C Rees; C Murdoch; J F Marshall; P A Cooper; M Bibby; G Li; S A Ali
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

Review 4.  Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models.

Authors:  Yukio Takeshita; Richard M Ransohoff
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

5.  Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.

Authors:  C Weber; T A Springer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

6.  A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics.

Authors:  Chunzhang Cao; Daniel A Lawrence; Dudley K Strickland; Li Zhang
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

7.  Leishmania infection impairs beta 1-integrin function and chemokine receptor expression in mononuclear phagocytes.

Authors:  Nathanael F Pinheiro; Micely D R Hermida; Mariana P Macedo; José Mengel; Andre Bafica; Washington L C dos-Santos
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

8.  MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Authors:  Sonia Vallet; Noopur Raje; Kenji Ishitsuka; Teru Hideshima; Klaus Podar; Shweta Chhetri; Samantha Pozzi; Iris Breitkreutz; Tanyel Kiziltepe; Hiroshi Yasui; Enrique M Ocio; Norihiko Shiraishi; Janice Jin; Yutaka Okawa; Hiroshi Ikeda; Siddhartha Mukherjee; Nileshwari Vaghela; Diana Cirstea; Marco Ladetto; Mario Boccadoro; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

9.  Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14+ CD16+ monocytes.

Authors:  Matias Jaureguiberry-Bravo; Lillie Lopez; Joan W Berman
Journal:  J Leukoc Biol       Date:  2018-05-23       Impact factor: 4.962

10.  Oxidized laminin-1 induces increased monocyte attachment and expression of ICAM-1 in endothelial cells.

Authors:  Elena Kostidou; Konstantina Topouridou; Angelos Daniilidis; Martha Kaloyianni; George Koliakos
Journal:  Int J Exp Pathol       Date:  2009-12       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.